Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellerant Therapeutics has received $1,683,503 Small Business Innovation Research (SBIR) phase 1 contract and a phase 2 option from the National Cancer Institute (NCI) to develop CLT-009, a human allogeneic Megakaryocyte Progenitor Cell therapy to treat thrombocytopenia in cancer patients.
Subscribe to our email newsletter
The SBIR contract will also allow the company to conduct studies to file an Investigational New Drug (IND) Application with the FDA in the next two years for CLT-009.
Cellerant Therapeutics chief executive officer Ram Mandalam said the contract will allow the company to not only leverage its experience in developing cellular therapies but also provide them with the ability to bring CLT-009 closer to the clinic.
”Our unique product portfolio, which now includes CLT-009, along with our CLT-008 – myeloid progenitor cell product and our therapeutic antibodies targeting cancer stem cells, demonstrates our continued commitment to developing novel products for the benefit of cancer patients," Mandalam added.
The previous studies conducted by Cellerant have shown that megakaryocyte progenitor cells were able to produce human platelets in preclinical models with in vivo functionality similar to that of normal human platelets.